ALFA News
Straight from the exchange filing
Every announcement Aurobindo Pharma has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Every Aurobindo Pharma announcement on ALFA FilingsSee filings →Reference market data from a third-party provider, as of the most recent story. Not a valuation or a recommendation.
Aurobindo Pharma receives USFDA final approval for its first MDI product, targeting a US$301 million market. The approval covers Beclomethasone Inhalation Aerosol.
Aurobindo Pharma subsidiary Lannett launches generic Advair Diskus in the US, marking its first inhalation product entry into the $908M respiratory market.
